erlotinib hydrochloride has been researched along with cudc 101 in 2 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (cudc 101) | Trials (cudc 101) | Recent Studies (post-2010) (cudc 101) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 39 | 2 | 35 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | cudc 101 (IC50) |
|---|---|---|---|
| Histone deacetylase 3 | Homo sapiens (human) | 0.1561 | |
| Tyrosine-protein kinase ABL1 | Homo sapiens (human) | 2.89 | |
| Epidermal growth factor receptor | Homo sapiens (human) | 0.0046 | |
| Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 0.0525 | |
| Tyrosine-protein kinase Lck | Homo sapiens (human) | 5.91 | |
| Tyrosine-protein kinase Lyn | Homo sapiens (human) | 0.84 | |
| Proto-oncogene tyrosine-protein kinase receptor Ret | Homo sapiens (human) | 3.2 | |
| Fibroblast growth factor receptor 2 | Homo sapiens (human) | 3.43 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.849 | |
| Receptor-type tyrosine-protein kinase FLT3 | Homo sapiens (human) | 1.5 | |
| Histone deacetylase 4 | Homo sapiens (human) | 0.1567 | |
| Fatty-acid amide hydrolase 1 | Rattus norvegicus (Norway rat) | 3.7086 | |
| Histone deacetylase 1 | Homo sapiens (human) | 0.1554 | |
| Histone deacetylase 7 | Homo sapiens (human) | 0.2081 | |
| Histone deacetylase 2 | Homo sapiens (human) | 0.1566 | |
| Polyamine deacetylase HDAC10 | Homo sapiens (human) | 0.1815 | |
| Histone deacetylase 11 | Homo sapiens (human) | 0.1806 | |
| Histone deacetylase 8 | Homo sapiens (human) | 0.1662 | |
| Histone deacetylase 6 | Homo sapiens (human) | 0.1555 | |
| Histone deacetylase 9 | Homo sapiens (human) | 0.1644 | |
| Histone deacetylase 5 | Homo sapiens (human) | 0.1564 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Atoyan, R; Cai, X; Lai, CJ; Ma, AW; Pursell, NW; Samson, ME; Savagner, P; Selmi, A; Voi, M; Wang, J; Xu, W | 1 |
| Biswas, L; Keechilat, P; Melge, AR; Mohan, CG; Panicker, PS | 1 |
2 other study(ies) available for erlotinib hydrochloride and cudc 101
| Article | Year |
|---|---|
Potential advantages of CUDC-101, a multitargeted HDAC, EGFR, and HER2 inhibitor, in treating drug resistance and preventing cancer cell migration and invasion.
Topics: Cadherins; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Neoplasm Invasiveness; Proto-Oncogene Proteins c-met; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms | 2013 |
Epidermal growth factor receptor (EGFR) structure-based bioactive pharmacophore models for identifying next-generation inhibitors against clinically relevant EGFR mutations.
Topics: Antineoplastic Agents; Computer-Aided Design; Databases, Pharmaceutical; Drug Design; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Hydroxamic Acids; Molecular Docking Simulation; Mutation; Protein Kinase Inhibitors; Quantitative Structure-Activity Relationship; Quinazolines; Small Molecule Libraries | 2017 |